Ticker LaunchIPO · SGMT
Sagimet Biosciences Inc.
Formerly 3-V Biosciences, Inc.
Sagimet Biosciences Inc. (SGMT) priced its initial public offering on Jul 17, 2023 at $16.00 per share, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $354.8M. Goodwin Procter advised the company and Cooley advised the underwriters.
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors. Its lead candidate, denifanstat, is an oral once-daily pill in a Phase 2b trial for nonalcoholic steatohepatitis (NASH).
- Status
- IPO
- Ticker
- SGMT
- Exchange
- Nasdaq Global Market
- Priced
- Jul 17, 2023
- IPO price
- $16.00
- Market cap at IPO price
- $354.8M
- First filed
- Apr 16, 2021
- Company counsel
- Goodwin Procter
- Underwriters' counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Apr 16, 2021
- Latest amendment Jul 10, 2023
- Final prospectus (424B4) Jul 17, 2023
- All filings on EDGAR CIK 1400118
Other Biotech & pharma IPOs in 2023
- Neumora Therapeutics, Inc.NMRA · Sep 18, 2023 · $250.1M
- Mira Pharmaceuticals, Inc.MIRA · Aug 4, 2023 · $8.9M
- Turnstone Biologics Corp.TSBX · Jul 24, 2023 · $80M
- Apogee Therapeutics, Inc.APGE · Jul 17, 2023
- 60 Degrees Pharmaceuticals, Inc.SXTP · Jul 13, 2023 · $7.5M
- Azitra, Inc.AZTR · Jun 21, 2023 · $7.5M